New Drug

J&J's Invokana clears FDA


The FDA has approved Janssen's Invokana (canagliflozin) for type 2 diabetes, giving J&J a first-to-market advantage in the SGLT-2 class.

Pent-up demand stands to drive Tecfidera, docs say

Pent-up demand stands to drive Tecfidera, docs say


Two-fifths of US neurologists polled said they're warehousing MS patients in anticipation of Tecfidera, though pricing worries could dampen sales.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.